Vimarsana
Biggest News Aggregation in the World

Page 45 - Development Operations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Development Operations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Development Operations Today - Breaking & Trending Today

Therapy Brands Announces Jason Sears as Senior Vice President, IT and Development Operations - Vimarsana News

Therapy Brands Announces Jason Sears as Senior Vice President, IT and Development Operations

/PRNewswire/ -- Therapy Brands is pleased to announce Jason Sears has joined the company as Senior Vice President, IT and Development Operations. In this role,...

Four Reasons ServiceNow Could Grow Faster Than Its 22% Target - Vimarsana News

Four Reasons ServiceNow Could Grow Faster Than Its 22% Target

ServiceNow's stock soared at 44% a year in the decade ending 2020. If it can grow revenue faster than 22%, that could continue.

Source: forbes.com
Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript - Vimarsana News

Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript

ASND earnings call for the period ending March 31, 2021.

Source: msn.com
IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort - Vimarsana News

IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort

IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort - Observed early clinical efficacy in first cohort of darovasertib plus crizotinib combination with tumor reduction in 2 of 2 evaluable MUM patients, including a partial response in a 3L patient with a 54% tumor reduction who is awaiting a confirmatory scan - Initiated darovasertib plus crizotinib combination Phase 1/2 dose expansion based on early clinical activity observed in first cohort; additional dose exploration ongoing News provided...

Forty8Fifty Labs Receives Atlassian Partner of the Year 2020: Services - Vimarsana News

Forty8Fifty Labs Receives Atlassian Partner of the Year 2020: Services

/PRNewswire/ -- Forty8Fifty Labs, the Agile and DevOps consultancy and subsidiary of Veristor Systems, today announced that it has received recognition as...